Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy?

Which do you think would win in a fight between gene editing and gene therapy?

Well, we might find out sooner than expected, because Vertex Pharmaceuticals (NASDAQ: VRTX) has doubled down on a partnership with gene editing pioneer CRISPR Therapeutics (NASDAQ: CRSP). Vertex didn't end its spending spree with exclusive rights to potential new muscular dystrophy treatments from CRISPR; it also splurged on a privately held gene editing start-up with a promising preclinical-stage Duchenne muscular dystrophy (DMD) candidate.